Johnson & Johnson: How Three Brothers and One Marble Slab in a Lobby Built the World's Most Trusted Healthcare Name

Most company mission statements sit quietly in an employee handbook, rarely tested and rarely remembered. Johnson & Johnson's sits carved into marble in its corporate lobby, and in 1982, the company proved, at enormous financial cost, that it actually meant every word.

Three Brothers Inspired by a Speech About Germs

In 1886, three brothers, Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson, founded Johnson & Johnson in New Brunswick, New Jersey. The idea for the company reportedly traces back to a speech given by antiseptic surgery advocate Joseph Lister in 1885, which convinced the brothers there was a real, urgent need for ready-to-use, sterile surgical dressings, a genuine gap in medical care at the time.

The founding itself carried a small element of chance. In January 1886, James Wood Johnson was riding a train through New Brunswick when he spotted a "for rent" sign on a factory building through the window. That building, the old Janeway and Carpenter factory on Neilson Street, became Johnson & Johnson's very first home. The company opened its doors with just 14 employees, eight women and six men, and began manufacturing the world's first mass-produced, sterile surgical supplies, along with medicated plasters and household products. Robert Wood Johnson served as the company's first president, and the brand's now-iconic cursive logo was drawn directly from James Wood Johnson's own signature.

Building Credibility Through Science, Not Just Sales

The young company moved quickly to establish scientific legitimacy. In 1888, it distributed 85,000 copies of a guide titled "Modern Methods of Antiseptic Wound Treatment," teaching doctors how to properly use its products in sterile surgery. In 1889, Johnson & Johnson hired local pharmacist Fred Kilmer as its scientific director, and one of his earliest and most significant achievements was pioneering an industrial sterilization process, replacing the labour-intensive hand-sterilisation methods employees had previously relied on, a genuinely revolutionary shift for the medical supplies industry at the time. The company continued expanding its consumer product lines over the following decades, adding Johnson's Baby Oil in 1935.

A Document Written Just Before Going Public

In 1943, as the company prepared for its initial public offering, Robert Wood Johnson II, grandson of the founder, wrote what became known as "Our Credo," a defining statement outlining the company's responsibilities, in order, to the patients and customers it served, its employees, the communities it operated in, and finally its shareholders. Under Johnson's leadership as chairman from 1932 to 1963, the company's revenues grew more than fifteenfold, expanding significantly during and after World War II, a period during which the company also guaranteed that employees who left for military service would have their jobs waiting when they returned. The Credo, inscribed on a marble slab that still stands in the company's corporate lobby today, became far more than a framed statement, it became the company's practical decision-making compass in moments that truly mattered.

The Crisis That Became a Case Study

That compass was tested in the most severe way imaginable in 1982. Between September 29 and October 1 of that year, an unknown individual laced bottles of Extra-Strength Tylenol capsules with cyanide, killing seven people in the Chicago area. At the time, Tylenol commanded roughly 35 percent of the US over-the-counter analgesic market and represented about 15 percent of Johnson & Johnson's total profits, making the crisis both a public safety emergency and a genuine existential threat to the business.

Johnson & Johnson's response, coordinated under CEO James E. Burke, who had become chairman in 1976, and guided by Corporate Vice President of Public Relations Lawrence G. Foster, was immediate and, for the era, remarkably decisive. The company issued warnings to hospitals and distributors nationwide, halted all Tylenol production and advertising, and on October 5, 1982, announced a full nationwide recall of Tylenol capsules, at a direct cost that ran into the hundreds of millions of dollars. Rather than downplaying the crisis or protecting short-term sales, the company chose to act in a way directly aligned with the priorities laid out in its own Credo four decades earlier, patients first, profits last. In the aftermath, Johnson & Johnson introduced tamper-resistant packaging for Tylenol, an innovation that went on to reshape safety standards across the entire consumer packaged goods industry. A second, smaller tampering incident followed in 1986, and combined, the two Tylenol crises are reported to have cost Johnson & Johnson more than $240 million and claimed eight lives in total. Despite the scale of the crisis, Tylenol recovered a significant share of its lost market position within months, and the company's handling of the incident became, and remains, one of the most widely taught case studies in crisis management anywhere in the world.

A Company That Kept Evolving

Johnson & Johnson's business continued to expand well beyond its original surgical supplies roots, notably with the 1953 establishment of Janssen Pharmaceutica in Belgium, which grew into a major driver of the company's pharmaceutical research and revenue. In a more recent structural shift, Johnson & Johnson spun off its consumer health division, home to well-known household names like Band-Aid, Tylenol, and Johnson's Baby products, into a separate publicly traded company called Kenvue in 2023, allowing Johnson & Johnson itself to focus more sharply on prescription pharmaceuticals and medical technology. Today, led by Chairman and CEO Joaquin Duato, the company reported revenue of $94.19 billion in its 2025 financial year, with roughly 138,200 employees worldwide, and ranks among the world's largest pharmaceutical and biotechnology companies by market capitalisation.

The Marketing Strategy: Let a Written Promise Guide Every Real Decision

What makes Johnson & Johnson genuinely distinctive as a brand is that its most powerful marketing asset was never an advertising campaign at all, it was a 1943 internal document that the company chose to actually follow when the stakes were highest. By publicly and visibly prioritising patient safety over short-term profit during the Tylenol crisis, at real, measurable financial cost, Johnson & Johnson didn't just manage a public relations emergency, it demonstrated its stated values under the most extreme pressure a company can face, turning "Our Credo" from a lobby decoration into tangible, lived proof of trustworthiness that no advertisement could ever manufacture on its own.

A Trust Built Over More Than a Century

Johnson & Johnson's journey, from three brothers responding to a speech about antiseptics to one of the most recognised names in global healthcare, is ultimately a story about the difference between writing down your values and actually living by them when it costs you the most. Nearly a century and a half later, that marble slab in the New Brunswick lobby still stands as a reminder of exactly how the company chose to prove it.